CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 12 enrolled
Drug / intervention
Coupled plasma filtration and adsorption (CPFA)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03312036
NCT03312036N/ACompleted

HEpatic Regeneration With COupled Plasma Filtration and Adsorption for Liver Extracorporeal Detoxification

IRCCS Azienda Ospedaliero-Universitaria di Bologna·interventional·Posted Oct 17, 2017·Updated Mar 17, 2021

In Brief

A clinical study evaluating Coupled plasma filtration and adsorption (CPFA) for Liver Failure, Acute and Liver Failure, Acute on Chronic. Completed, enrolled 12 participants across 1 site.

Detailed Summary

CPFA is currently used in the treatment of severe sepsis with the intention of removing the proinflammatory mediators from the systemic circulation. Some evidence exists about the bilirubin adsorbing ability of the neutral styrenic resin which is part of the extracorporeal circuit of CPFA. The aim of this study is to assess efficacy and safety of CPFA in extracorporeal detoxification of liver toxins in patients affected by acute or acute-on-chronic liver failure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesItaly
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 17, 2017
Enrollment StartJun 6, 2013
Primary CompletionDec 21, 2018
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 8.7 years ago

Interventions

Coupled plasma filtration and adsorption (CPFA)device

Patients affected by acute or acute on chronic liver failure are enrolled to undergo CPFA extracorporeal treatments and the standard medical therapy to recover their basal liver function or as a "bridge" to liver transplantation